Abstract: Estradiol (E 2 ) is a steroid hormone whose physiological actions are mainly mediated by its interaction with intracellular estrogen receptors (ER) leading to modification on the mRNA and protein synthesis in its target cells. However, estrogens can also activate several intracellular signal transduction cascades by non-genomic mechanisms. Estrogens must be inactivated and removed from blood through its conversion to soluble compounds with an apparent low estrogenic activity and decreased affinity for ER. In this context, 2-methoxyestradiol (2ME 2 ) is generated by a sequential hydroxylation of E 2 via the enzyme cytochrome P450 isoform 1A1 to produce 2-hydroxyestradiol (2OHE 2 ) followed by a conjugation reaction catalyzed by the enzyme Catechol-O-Methyltransferase generating 2ME 2 from 2OHE 2 . Recent evidence indicates that physiological concentration of 2ME 2 may regulate several biological processes while high concentrations of this metabolite may induce pathophysiological alterations in several tissues. In the last years, 2ME 2 has also been described as a promising anticancer drug although its cellular and molecular mechanisms are still being disclosed. Herein, we will review the available literature concerning the role of 2ME 2 in health and disease. We will focus on to describing the intracellular mechanisms by which 2ME 2 exerts its effects on reproductive and non-reproductive tissues. The promising anticancer effects of 2ME 2 and its synthetic derivatives will also be discussed. Finally, a group of 2ME 2 -target genes that could be used as biomarkers of 2ME 2 under physiological or pathophysiological conditions will be reviewed.
INTRODUCTION
Estradiol (E 2 ) is a pleiotropic hormone that regulates a wide variety of physiological functions in the reproductive tract, mammary gland, bones, brain, blood vessels and heart [1] [2] [3] [4] [5] [6] . The canonical mechanism by which E 2 regulates its target cells, involves binding to estrogen receptor α (ESR1) and/or β (ESR2) and modification of gene expression [7] . However, it has also been reported that E 2 may modulate the physiology of its target cells activating several intracellular signal transduction cascades by non-genomic mechanisms [8, 9] .
Estradiol is removed from the blood by a metabolic inactivation that requires biotransformation to less estrogenic compounds. Although conversion of E 2 to inactive metabolites occurs mainly in the liver, some peripheral organs including breast, uterus, placenta, oviduct and brain express the enzymes required to inactive estradiol [10, 11] . The subsequent conversion of E 2 to hydroxyestradiols and *Address correspondence to this author at the Laboratorio de Inmunología de la Reproducción, Facultad de Química y Biología, Universidad de Santiago de Chile, Alameda 3363, Casilla 40, Correo 33, Santiago, Chile; Tel:/Fax: 6812808; E-mail: pedro.orihuela@usach.cl then to methoxyestradiols is one of the most recognized enzymatic pathways that inactive E 2 [12] . When methoxyestradiols were characterized they were catalogued as inactive molecules without a biological role. However, it has also been demonstrated that 2-methoxyestradiol (2ME 2 ) may exert physiological actions in different organs and tissues and that an unbalanced E 2 metabolization to 2-hydroxyestradiol (2OHE 2 ) and 2ME 2 could be the responsible factor for several diseases including infertility, cancer or preeclampsia [13] . In this context, pharmacological doses of 2ME 2 have been tested as a promissory anticancer therapeutic strategy based on its effects on the angiogenesis and cellular proliferation of tumour cells [14] . The present review will describe the available literature concerning the role of 2ME 2 in health and disease. The intracellular mechanisms by which 2ME 2 exerts its effects on reproductive and non-reproductive tissues and the promising anticancer effects of 2ME 2 and its synthetic derivatives will be discussed. Finally, a group of 2ME 2 -target genes that could be used as biomarkers of 2ME 2 under physiological or pathophysiological conditions will be reviewed.
GENERATION OF 2-METHOXYESTRADIOL
Estradiol is mostly inactivated to 17β-estrone through an oxidative reaction catalyzed by the enzyme 17β-hydroxysteroid dehydrogenase (17β-HSD) [15] . Furthermore, other enzymatic modifications to inactive E 2 have been described in the last years [12] . These reactions include sulfonation catalyzed by several estrogen sulfotransferases, O-methylations catalyzed by the enzyme Catechol-OMethyltransferase (COMT), hydroxylations catalyzed by several cytochrome P450s isoforms enzymes and glucuronidations catalyzed by UDP-glucuronosyltransferases. Although, these reactions were firstly characterized in the liver, some enzymes that mediate these effects have been found in several peripheral tissues such as breast, uterus, placenta and brain [10] suggesting that these organs have also the ability to inactive E 2 by these pathways.
Estradiol is mainly inactivated through its conversion to 2OHE 2 and subsequent generation of 2ME 2 in extra hepatic tissues (Fig. 1) . These reactions involve a first oxidation in the carbon 2 inside the aromatic A-ring of E 2 , catalyzed by the enzyme Cytochrome P450 isoform 1A1 (CYP1A1), generating a molecule of 2OHE 2 . Then, the hydroxyl group previously added is replaced by a methyl group through a conjugation reaction catalyzed by the enzyme COMT to generate a molecule of 2ME 2 [12] . As CYP1A1 and COMT are expressed in the oviduct [11] ), ovary [16] , endometrium [17] , placenta [18, 19] , prostate [20] and testis [21] it is feasible to postulate that 2ME 2 could also be locally generated from E 2 in these organs.
CYP1A1 has the ability to metabolize several exogenous and endogenous compounds as E 2 and xenobiotics via an NADPH-dependent oxidative metabolism reaction [22] . CYP1A1 is normally expressed at low levels in different tissues and its expression is regulated by different biological compounds such as 6-Formylindolo(3,2-b)carbazole (a tryptophan-derived), bilirubin or eicosanoids [23] . However, an increased expression of this enzyme has been reported in cancer cells [24, 25] suggesting a role of CYP1A1 in this pathology. It has been documented that several toxic compounds associated with cancer etiology are able to increase CYP1A1 expression as for instance cigarette smoke condensate [26, 27] and dioxin [28, 29] .
On the other hand, COMT enzyme has the ability to add a methyl group (provided from S-adenosyl-l-methionine) to several molecules such as hydroxyestradiols and catecholamines [30] by an enzymatic reaction that requires Mg
2+
. This enzyme has two active isoforms encoded by the same gene and they are known as the cytoplasmic soluble form (S-COMT) and a membrane-bound form (MB-COMT). Both isoforms are identical except by an N-terminal extension of 50 amino acids in the amino-terminal in M-COMT, which is responsible for its anchorage to the endoplasmic reticulum membranes [30] .
MECHANISMS OF ACTION OF 2-METHOXYE-STRADIOL
A variety of biological effects of 2ME 2 reported in the literature are ER independent. However, in some few cases, these effects require a functional ER [11, 31, 32] . Here, the most well known cellular and molecular mechanisms exerted by 2ME 2 on its target cells will be briefly reviewed. 
Fig. (1).
Generation of 2-methoxyestradiol (2ME 2 ) from estradiol (E 2 ). In hepatic and extrahepatic tissues, E 2 is metabolized to 2-hydroxyestradiol (2OHE 2 ) by CYP1A1 and then 2OHE 2 is metabolized to 2ME 2 by COMT.
Depolarization of Microtubules
One of the first characterized effects of 2ME 2 was its ability to inhibit tubulin polymerization [33] [34] [35] . The molecular mechanism consists in a direct interaction between 2ME 2 and tubulin protein to inhibit the phases of nucleation and propagation during tubulin assembly [33] . Thus, 2ME 2 induces mitotic perturbations and death in cells with a high proliferative rate [36] . It has been proposed that this effect is the most important mechanism exerted by 2ME 2 to induce cell death in cancer cells [37] .
Reactive Oxygen Species (ROS)
The ability of 2ME 2 to induce ROS or block its production seems to depend on the cell types. Thus, 2ME 2 induced ROS production to decrease cell viability in the MCF7 [38] , nasopharyngeal carcinoma [39] , ovarian cancer [40] or human neuroblastoma cells [41, 42] . On the other hand, 2ME 2 blocked ROS production in non-cancer cells as the normal mouse spleen or swine granulosa cells [43, 44] .
HIF-1α Downregulation
One of the most characterized physiological effects of 2ME 2 is its ability to down-regulate the expression of the hypoxia-inducible factor 1 alpha (HIF-1α) protein. This is a transcription factor induced under hypoxic conditions that regulates the expression of several molecules related to cell proliferation, angiogenesis and metabolism such as the vascular endothelial growth factor (VEGF) [45, 46] . Despite HIF-1α expression is generally associated with cell survival, high levels of this transcription factor have been related with several pathological conditions such as allergic rhinitis [47, 48] , traumatic brain injury [49, 50] or preeclampsia [51, 52] . Protein stability and nuclear location of HIF-1α are decreased by 2ME 2 [50] leading to changes both in the microtubules polymerization and in the intracellular free radical levels [53] [54] [55] . This 2ME 2 effect is related with a successful placentation process described later in this review.
Modulation of Protein Phosphorylation and Kinases Activity
It has been reported that 2ME 2 modulates phosphorylation status of different proteins to exert its biological or pharmacological actions. Thus, 2ME 2 induces ERK 1/2 phosphorylation to down-regulate synthesis of Angiotensin type 1 receptor and endothelin 1 in liver epithelial cells [56] and coronary artery endothelial cells [57] , respectively. Furthermore, 2ME 2 decreases ERK1/2 phosphorylation to inhibit cell growth in human aortic smooth muscle cells [58] .
On the other hand, 2ME 2 activates different protein kinases to induce cell death in cancer cells. For example, 2ME 2 activates JNK kinases in prostate cancer cells [59] , Ewing sarcoma cells [60, 61] and nasopharyngeal carcinoma cells [62] to induce cell death by mitochondrial-dependent apoptotic pathways and/or autophagy. Furthermore, 2ME 2 activates a RNA-dependent protein kinase (PKR) [63] to induce autophagy in osteosarcoma cells and induces apoptosis in esophageal carcinoma cells by increasing cdc2 kinase activity [64] .
Smooth Muscle Contraction
A poorly explored effect of 2ME 2 is its ability to modulate contraction of vascular and non-vascular smooth muscle cells. As 2ME 2 inhibits phenylephrine-induced tension in aorta [65] and KCl-induced contraction in coronary artery [66] it is probable that 2ME 2 has a relaxing effect on the vascular smooth muscle cells. Interestingly, 2ME 2 exerts these effects by ER independent mechanisms although it requires an intact endothelium. On the other hand, 2ME 2 attenuates KCl-induced uterine contraction by a non-genomic mechanism in non-vascular smooth muscle cells [67] .
REPRODUCTIVE EFFECTS OF 2-METHOXY-ESTRADIOL
The biological role of estrogens in the male and female reproductive systems involves regulation of the gametogenesis, transport of gametes and embryos, blastocyst implantation, pregnancy, lactation and sexual development [68] . In the testis, expression and enzymatic activity of the proteins responsible to produce 2ME 2 has been reported in several mammalian species. CYP1B1 expression was reported in human [69] [70] [71] and rat [72, 73] while CYP1A1 has been detected in human [71] , mouse [74] , and rat [75] . Furthermore, expression and/or activity of COMT have been reported in mouse [76] and human testes [77] . The biological and/or pathophysiological effects of 2ME 2 in the mammalian testis are unknown although it has recently been reported that high concentration of 2ME 2 decreases viability of Sertoli [78] and Leydig cells [79] . This suggests that an increased intratesticular concentration of 2ME 2 could have implications for male infertility. Interestingly, 2ME 2 exerts these deleterious effects inducing DNA fragmentation by caspase-independent mechanisms [78, 79] .
In contrast to the testicular cells, there are more abundant data on the physiological role of 2ME 2 in the mammalian ovary. According with the literature, CYP1A1 and COMT are present in the human ovary [12] and it has been reported that during the menstrual cycle, plasma levels of 2ME 2 are higher in the luteal than in the follicular phase [80] . Furthermore, levels of 2ME 2 in the follicular fluid are directly correlated with the follicle size in the pig [81] . On the other hand, an excessive production of 2ME 2 could be involved in the follicular arrest found in women with polycystic ovarian syndrome since high levels of 2ME 2 inhibited proliferation of the granulose cells [82] .
In the rat oviduct, the effect of 2ME 2 on the oviductal egg transport is dependent of the occurrence of mating. Thus, it has been reported that 2ME 2 shortens the time of permanence of the eggs from 72 h to less of 24 h in the oviduct of unmated although it had no effect in mated rats [11] . Moreover, the effect of 2ME 2 on the oviductal egg transport is through a non-genomic mechanism involving participation of the ER and the signaling cascades of cAMP-PKA in the oviductal cells [11, 83, 84] . It has recently been reported that the cytokine TNF-α is able to shutdown this 2ME 2 non-genomic signaling in the rat oviduct [84] indicating an interaction between cytokines and estrogen metabolites in the female reproductive tract. The physiological relevance of this phenomenon is associated with the prevention of the deleterious effects of 2ME 2 on the first stages of the embryo development [85] . In this context, we have recently found that a pharmacological dose of 2ME 2 administered to pregnant mice is able to inhibit embryo implantation (unpublished observations). It is postulated that this effect of 2ME 2 is mediated by an increase in the uterine secretion of the extracellular matrix protein F-spondin blocking the interaction between endometrial integrin α v β 3 and its ligand localized in the blastocyst [86] .
In ovariectomized rats, 2ME 2 delivered at a 1 µg/h rate by a subcutaneously implanted osmotic pump did not exert uterotrophic effects although it regulated bone metabolism [87, 88] . Rincon-Rodriguez et al. [86] showed that 2ME 2 (0.1-10 µg/mice) injected intraperitoneally during 7 days to prepuberal mouse did not change the uterine wet weight and height of epithelial cells in endometrium. In contrast, Sibonga et al. [88] observed that 2ME 2 (20 -40 mg/kg/day) administered subcutaneously to ovariectomized rats produced uterine hypertrophy and increased uterine epithelial thickness. These divergent results could be explained by a lower binding affinity of 2ME 2 for ER as compared with E 2 . It also indicates that murine endometrium is responsive to 2ME 2 .
In human endometrial tissue, S-COMT and M-COMT are expressed during the menstrual cycle. In this context, high immunoreactivity of S-COMT is observed in the proliferative phase while low expression of S-COMT occurs in the secretory phase suggesting up-regulation of COMT by estrogen and down-regulation by progesterone. This could be important to maintain the homeostasis of this tissue [82] . Endometriosis affects 10% of premenopausal women [89, 90] although the pathogenesis of this condition is not clearly understood. Singh et al. [91] reported the expression of CYP1A1 and CYP1B1 in eutopic and ectopic endometria from women with endometriosis suggesting participation of the estrogen metabolic pathway in this pathology. In a female mice endometriosis model, 2ME 2 induced suppression of endometriotic lesions [92] suggesting that decreased local 2ME 2 production in the ectopic endometrium may be one of the factors that promotes the survival of endometriotic tissue [92] .
On the other hand, preeclampsia is a maternal endothelial dysfunction associated with hypertension, proteinuria and placental hypoxia during pregnancy [93] . This condition affects approximately 5% of all pregnancies worldwide and it is related with maternal and perinatal morbidity and mortality [94, 95] , preterm birth or intrauterine growth foetal restriction [93] . It is postulated that preeclampsia is produced by an imbalance between expression and/or action of pro and antiangiogenic factors, which generates a poor trophoblastic invasion and incomplete spiral artery remodelling during early pregnancy [96, 97] . In the last years, it has also been proposed that a decreased 2ME 2 production during mild pregnancy is one of the first factors associated with preeclampsia [19, 35, 98] . The mechanisms by which 2ME 2 levels are decreased in the preeclampsia may involve reduced expression and/or activity of M-COMT and S-COMT in the placenta [19, 52] . The human COMT gene is located on chromosome 22 where it encodes for S-COMT and M-COMT [30] . COMT gene has several polymorphic sites that are associated with a high or low expression and/or enzymatic activity of COMT. For instance, COMT gene contains several single nucleotide polymorphisms as the SNPs rs4680, which determines a G/A transition (codon 158 in M-COMT and codon 108 in S-COMT gene sequence) leading to a substitution of valine by methionine. It has been determined that this methionine substitution generates a COMT enzyme with a 3-fold reduction in its protein activity compared with native COMT [30] . Some studies have found that women with preeclampsia have a high prevalence of Val158 substitution compared to normotensive pregnant women [99, 100] . This could indicate that a decreased production of 2ME 2 observed in preeclamptic women is due to the presence of this polymorphism. On the other hand, some preeclamptic women also have decreased COMT expression in their placental tissue although the mechanisms involved in this phenomenon are not well elucidated [19] . The role of 2ME 2 on the human placentation may be associated with the regulation of the expression and/or activity of HIF-1α in the placental tissue as shown in the human cytotrophoblast cell line HTR-8 [51] . Expression of HIF-1α is highly increased by the hypoxic environment present during the early placentation [51, 101] . However, HIF-1α levels decrease during mild placentation stage so that increased levels of this transcription factor can prevent a normal placentation. This is supported by the fact that HIF-1α overexpression in the uterus of pregnant mice is associated with fetal intrauterine growth restriction, decreased placental weight and placental abnormalities as observed in preeclamptic women [102] . Moreover, HIF-1α is highly increased in the placenta of preeclamptic women compared with normotensive pregnant women [103] . The mechanism by which high HIF-1α expression is associated with preeclampsia may involve inhibition of the VEGF signalling pathway and impaired placental perfusion [104] .
NON-REPRODUCTIVE EFFECTS OF 2-METHO-XYESTRADIOL
Estradiol may induce beneficial effects on the female physiology. Compared with age-matched men, the rate of progression of cardiovascular, renal, bone or neural diseases in premenopausal women is low. However, the progression of these pathologies is accelerated with the menopause occurrence and it is necessary hormone replacement therapy [105] . The beneficial effects of E 2 on the vasculature are associated with modifications of lipoproteins, inhibition of atherosclerosis and regulation of the vascular tone [106] . A role for estrogen metabolites on the effect of E 2 in the vascular system was proposed because E 2 prevents atherosclerosis by inhibiting the neointima formation in double knockout ESR1 and ESR2 mice [107] . Furthermore, 2ME 2 is associated with inhibition of vaso-oclusive disorders because it inhibited synthesis of endothelin-1 in porcine coronary artery endothelial cells [57] . Moreover, 2ME 2 down-regulated the expression of Angiotensin type I receptor that is involved in blood vessels inflammation [108] . This effect is mediated by previous binding of 2ME 2 with a newly discovered membrane estrogen receptor GPR30 and not requires activation of the classical ER [108] . On the other hand, it has also been reported that CYPA1A1, CYP1B1 and COMT were expressed in vascular tissues of several mammalian species [57] .
The role of 2ME 2 on the brain physiology is mainly associated with its inhibitory effect on the HIF-1α expression. Increased expression of HIF-1α is implicated in many cerebrovascular disorders that may be induced by an acute hypoxic environment in the neuronal cells [109] . In this context, inhibition of the HIF-1α activity or expression imparts neuroprotection to adult rodents followinga cerebral ischemia [110, 111] . Thus, it is now suggested that pharmacological targeting of HIF-1α activity may be a promising therapeutic strategy to attenuate the secondary brain damage following a cerebral stroke or traumatic brain injury. Considering that 2ME 2 is able to inhibit HIF-1α expression in cancer cell lines and in HUVEC cells [53, 112] several laboratories have conducted investigations to determine the beneficial effects of 2ME 2 following brain injury. Intraperitoneal administration of 2ME 2 (10-20 mg/kg body weight) 30 min after brain trauma reduced the progression of secondary brain damage in adult mice [50] . Using a rat pup hypoxic-ischemic model, Chen et al. [111] showed that 2ME 2 administered 5 min after a hypoxic stimulus reduced brain damage as shown by increased preservation of the blood-brain barrier, attenuation of brain edema and inhibition of neural apoptosis. The molecular basis by which 2ME 2 influences the nervous system could be related with changes on COMT activity since genetic and/or epigenetic alterations in the COMT expression are associated with mental disorders [113, 114] .
The effects of 2ME 2 on renal tissues are associated with a attenuation of glomeruloe sclerosis since 2ME 2 stimulates synthesis of nitric oxide (NO) in glomerular endothelial cells and inhibits abnormal growth of glomerular mesangial cells via regulation of cAMP production [115, 116] .
Altogether, these data reinforce the concept that the protective effects of E 2 on the female health may be in part mediated by a previous conversion of E 2 to 2ME 2 in its target organs.
EFFECTS OF 2-METHOXYESTRADIOL ON TUMOR CELLS
It is now well recognized that 2ME 2 can inhibit cell growth and induce cell death in a variety of malignant cell lines including lung and colon carcinoma, melanoma, and cancers from the reproductive system [12, 80, [117] [118] [119] [120] . The antitumoral effects of 2ME 2 are normally independent of ER activation and involve suppression of tumor cells growth by different molecular mechanisms. These include inhibition of angiogenesis [34, 35, 120] , induction of apoptosis through caspases-dependent [121] or caspases-independent mechanisms [122] , and inhibition of β-tubulin polymerization [33] [34] [35] . The ability of 2ME 2 to inhibit β-tubulin polymerization is correlated with its inhibitory effect on HIF-1α activity in tumor cells [112] . On the other hand, various reports suggest a correlation between COMT polymorphisms and cancer risks that could be associated with patient ethnicity. Thus, a specific val158 met COMT polymorphism has been associated with a decreased risk of uterine leiomyoma while a COMT Val/Val genotype is correlated with an increased endometrial cancer risk in some Asian populations [123, 124] .
CLINICAL USE OF 2-METHOXYESTRADIOL
Clinical use of 2ME 2 is mainly limited by its poor water solubility and low bioavailability [125, 126] . Indeed, a clinical trial of 2ME 2 was cancelled because its plasma concentrations after oral administration were lower than the effective dose [127] . Experiments in rats demonstrated that 2ME 2 could be detected in the plasma until 120 minutes following intravenous administration while 2ME 2 was undetectable when it was given by an oral route. This suggests that 2ME 2 may be rapidly metabolized in the gastrointestinal tract [128] . According to this assumption, Guo et al. [129] performed an in situ rat intestinal recirculation perfusion technique and demonstrated that the absorption rate constant of 2ME 2 was independent of the different 2ME 2 concentrations used in this experiment. This corroborates that the low bioavailability of 2ME 2 when it is administered orally is related to its metabolic transformation rather than its poor absorption rate in the intestinal epithelium. In this context, 2ME 2 levels found in the urine of cancer patients treated with an oral dose of 2ME 2 were close to 0.002% from the total dose administered [130] . On the other hand, plasma levels of 2-methoxyestrone (2ME1) were 10-20 fold higher than 2ME 2 after a continuous oral administration of 2ME 2 in patients with different types of cancer [131] [132] [133] [134] [135] . This indicates that 2ME 2 is mainly metabolized and inactivated through its conversion to 2ME1 probably by the enzyme 17β-HSD [131] [132] [133] [134] [135] . This hypothesis is supported by the fact that two breast cancer cell lines insensitive to the anti-proliferative and cytotoxic effects of 2ME 2 (ZR75 and MDA-MB-231 cells) have a higher 17β-HSD activity than other breast cancer cell lines sensitive to 2ME 2 (MCF-7, T-47D or MDA-MB-435 cells) [136, 137] . Furthermore, MCF-7 cells transfected with the enzyme17β-HSD were insensitive to 2ME 2 [136] . Interestingly, the enzyme 17β-HSD is also highly expressed in the human gastrointestinal tract [138] .
It has been shown that only 1% from 2ME 2 given orally to cancer patients was found as glucuronides in the urine whereas oxidative or sulfated metabolites of 2ME 2 were very low or undetectable [130] . This could indicate that glucuronidations might be the major pathway by which 2ME 2 is inactivated before to be excreted.
Attempts to overcome the limitation of the 2ME 2 low bioavailability have involved different strategies to develop new drug formulations. The formulation of 2ME 2 as a nanosuspension in conjunction with poly-(organophosphazenes) has been recently designed [139] . The hydrogel containing a relatively low concentration of 2ME 2 demonstrated improved antitumor and antiangiogenic activity in a mouse breast tumor model compared with the original delivery method [125] . A further approach to overcome the problem of low plasma availability could be to develop engineer modifications into the structure of 2ME 2 that increase its half-life and decrease the time-course of excretion. In this context, preparation of 2ME 2 encapsulated or adsorbed in magnetic nanoparticles (i.e. alluminosilicate zeolites) may be a good experimental strategy to deliver this drug specifically into the tumor cells [140] .
On the other hand, Stubelius et al. [31] have found that 2ME 2 increased the Natural Killer (NK) and T cells population from the bone marrow, spleen and liver in ovariectomized mice indicating a probable pharmacological role of 2ME 2 on the immune system. Furthermore, it has been reported that mice lacking COMT have an altered immune phenotype as shown by an increase in the number of T and B-lymphocytes and a high frequency of neutrophils. Furthermore, NK cell population shifted toward less mature cells [141] . Therefore, some cautions must be taken to administer pharmacological doses of 2ME 2 since unwanted effects on the system immune could occur in some patients.
SPECIAL FORMULATIONS OF 2-METHOXY-ESTRADIOL OR ITS DERIVATIVES AS PROMI-SSORY DRUGS IN CANCER TREATMENT
2ME 2 has already been tested as a pharmacological treatment in patients with hormone-refractory prostate cancer [131] and with different solid tumors [127] . In both cases, 2ME 2 administered as oral capsules was well tolerated by patients although it showed modest anticancer activity probably by its rapid metabolic degradation to inactive compounds (especially to 2ME1), which significantly decreased its bioavailability. For this, several attempts have been performed in order to produce formulations of 2ME 2 or its analogs that conserve its pharmacological properties, but with a longer bioavailability than natural 2ME 2 . Here, one formulation and two 2ME 2 derivatives (Fig. 2) that have been extensively studied are described.
-Panzem™: The first commercially available preparation of 2ME 2 was Panzem™ (Entremed Inc, now called CASI Pharmaceuticals Inc. Rockville, MD, USA). In this formulation, 2ME 2 is reduced to nanometer-sized particles (nanocrystal colloidal dispersion) to delay its degradation. This compound is administered orally and the maximum tolerated dose has been estimated in 1000 mg administered four times daily [132] . Panzem™ has been assayed in several phase I and II clinical trialsin patients with breast cancer [133] , different refractory solid tumors [134] , ovarian cancer, primary peritoneal carcinomatosis [132] , metastatic prostate cancer [135] , metastatic kidney cancer [142] or advanced carcinoid tumors [143] . In these studies, Panzem™ was generally well tolerated although fatigue was the most common adverse effect in almost all patients. This compound provided better bioavailability than 2ME 2 and also had some antitumor actions. However, its effect at clinical level was rather modest probably because it was tested in very aggressive metastatic cancer or by its even low bioavailability. With the purpose to enhance its clinical effects, Panzem™ has been administered concomitantly with a multitargeted receptor tyrosine kinase inhibitor (Sunitinib) in patients with metastatic renal cell carcinoma [142] or with an angiogenesis inhibitor (Bevacizumab) in patients with advanced carcinoid tumors [143] . However, the results obtained at clinical level were not very conclusive to demonstrate efficacy in these patients. ENMD-1198 ([3-carboxyamide-2-methoxyestra-1,3,5  (10) 
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16-tetraene])
This 2ME 2 derivative also known as C24-883 or ENMD-0998 was developed by CASI Pharmaceuticals Inc. (Rockville, MD, USA) as an oral formulation. This compound has the ability to prevent microtubule polymerization, decrease HIF-1α expression and induce apoptosis in cancer cells. Furthermore, it shows a significant increase in its bioavailability compared with 2ME 2 [144] . ENMD-1198 also inhibits growth and vascularization of human hepatocellular carcinoma cells in vitro and in vivo [145] and reduces breast tumor burden in vivo [146] . This compound was tested in a clinical trial in patients with different advanced cancers [147] . The results obtained showed that ENMD-1198 was generally well tolerated although fatigue was the main side effect (55%). According with the results obtained in this study, ENMD-1198 may be a promissory 2ME 2 derivative drug in cancer treatment since it prolonged disease stabilization in some patients [147] .
STX140 (2-Methoxyestradiol-3,17-O,O-bissulphamate)
This 2ME 2 derivative consists of a 2ME 2 molecule with a sulfamate group added in carbons 3 and 17. Firstly tested in 2003, this compound inhibited proliferation of breast cancer cell lines that were resistant and non-resistant to doxorubicin and mitoxantrone [148] . Moreover, the required dose of Fig. (2) . Molecular structures of 2ME 2 and its derivatives STX140 and ENMD1198.
STX140 was significantly lower than the 2ME 2 dose to inhibit breast cancer cells growth in vitro [149] and in vivo [150, 151] . The mechanisms by which STX140 induces apoptosis and/or autophagia in cancer cells are similar to 2ME 2 , and involve an increase in the intracellular reactive oxygen species [152] and cell cycle blockade at G2M stage [153] . Interestingly, STX140 did not affect cell viability in a non-tumorigenic human breast cell line [154] . This compound also inhibited initiation and progression of mammary tumors in adult mice [155] suggesting that STX140 is a promissory 2ME 2 analog that can be potentially used in human breast cancer.
Independent of these promissory compounds, watersoluble 2ME 2 prodrugs that can be endogenously metabolized to 2ME 2 has recently been synthesized. Edsall et al. [156] developed and tested the 2ME 2 prodrugs 3-phosphate (2ME 2 -3P),17-phosphate (2ME 2 -17P) and 3,17-diphosphate (2ME 2 -3,17DP). They demonstrated that 2ME 2 -3P and 2ME 2 -17P were metabolized to 2ME 2 . Furthermore, 2ME 2 -3P also had cytotoxic effects like 2ME 2 in different cancer cell lines and in an in vivo lung carcinoma metastasis model [156] . Moreover, Kambhampati et al. [128] recently synthesized and studied the biological effects of 2-methoxy-3-yloxymethyl phosphate-17-acetoxyestradiol (2-ME2-PD1), a second generation of 2ME 2 prodrugs. They found that 2-ME2-PD1 was transformed to 2ME 2 and is more effective than 2ME 2 to induce antiproliferative and anticancer effects in esophageal cancer as assessed in a xenograft mouse model [128] .
POTENTIAL BIOMARKERS OF 2-METHOXY-ESTRADIOL IN HEALTH AND DISEASE
Micro array analysis is a useful tool to establish gene expression profiling in several tissues and organs. This experimental approach has been used to explore possible molecular markers involved in the antiangiogenic and proapototic effects of 2ME 2 . The apoptotic effect of 2ME 2 on multiple myeloma cells are associated with the expression of genes related to the unfold protein response in the endoplasmic reticulum, heat shock proteins and the ubiquitin-proteasome pathway, and structural/cytoskeleton genes [157] . Utilizing 2ME 2 -treated female human aortic smooth muscle cells, Barchiesi et al. [158] reported changes in the gene expression including inhibition of molecules relevant to the cell cycle, tubulin polymerization, cholesterol and steroid synthesis, and induction of metalloproteases and ciclooxygensae-2. Rincon-Rodriguez et al. [86] have recently described for the first time a group of genes induced by 2ME 2 in the prepuberal mouse uterus. As this group of genes only correspond to the 0.23% from the total of analysed genes it is probable that the effects of 2ME 2 involve a fine-tuning on the uterine tissues. Interestingly, a group of genes (0.04%) was regulated by 2ME 2, but not by E 2 suggesting that 2ME 2 uses intracellular signalling pathways independently of E 2 . On the other hand, with the purpose to find new molecular markers that could be useful as a prognostic of the anticancer effects of 2ME 2 we compared the effect of an antitumoral or non-antitumoral concentration of 2ME 2 on the mRNA level of stearoyl-coenzyme A desaturase 2 (scd2) [159] , sorting nexin 6 (snx6) [160] and F-spondin (spon1) [161] in the cancer cell line Ishikawa. Interestingly, spon1 and snx6 were increased following treatment with a anti-tumoral concentration of 2ME 2 , indicating that spon1 and scd2 could participate in the signaling pathway by which 2ME 2 exerts apoptotic activity in tumoral cell lines [14] . Both transcripts could also be used as biomarkers in the diagnostic of cancer patients with potential probabilities for treatment with 2ME 2 .
CONCLUDING REMARKS
Given the crucial role of E 2 in the human physiology, a new research avenue has now been open related with the role of estrogen metabolites as responsible for the E 2 physiological and pathophysiological actions. Recent evidence indicates that physiological and pathophysiological levels of 2ME 2 may regulate various biological processes on reproductive tissues, where it changes profile gene expression in the uterus, alters egg transport in the oviduct and affects male infertility. Furthermore, imbalance in the production of 2ME 2 from catechol estrogens could cause several diseases as endometriosis, preeclampsia or cardiovascular disorders. Altogether, it highlights a new concept in the endocrine physiology postulating that the protective effects of E 2 could be in part mediated by a previous conversion of E 2 to 2ME 2 in its target organs. This also demonstrates that 2ME is an important component in the intracellular E 2 signaling pathway. On the other hand, 2ME 2 has been described as a promising anticancer drug although the molecular mechanisms by which this E 2 metabolite induces apoptotic and antiangiogenic activity in tumor cells are recently being disclosed. The potential therapeutic applications of 2ME in the anticancer strategy have been limited by its poor water solubility and low bioavailability preventing to reach the adequate plasma concentrations relative to its effective dose. For this, several attempts have been performed to produce preparations of 2ME 2 or its analogs, which conserve its pharmacological properties although with a longer bioavailability than natural 2ME 2 . Panzem™, ENMD-1198 and STX140 are new formulations that are actually being developed in clinical trails although with modest results. A further approach to overcome 2ME 2 low plasma bioavailability could be to develop engineer modifications into the structure of 2ME 2 , which permits its incorporation in polymeric or magnetic nanoparticles delivering this drug specifically into the tumor cells. In addition, the search for new biomarkers associated with the physiological and pathophysiological effects of 2ME could provide a new impulse in our understanding of the molecular basis of E 2 actions on its target organs. Interestingly, transcripts that respond to 2ME in primary cell cultures from cancer patients could also be used as therapeutic biomarkers to enhance the probabilities for 2ME 2 treatment in these patients.
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